BRIM Biotechnology, Inc.
BRIM Biotechnology: bringing transformational treatments to patients sooner. BRIM Biotechnology applies integrated and efficient translational science to develop new treatments that help combat and cure disease. The company was founded in August 2013 in Taiwan by a team of seasoned, entrepreneurial global pharma experts. We believe medicines with the potential to cure disease, or significantly improve patient lives, should be affordable to health systems and accessible to patients world-wide.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2013
Welcome
Bringing transformational treatments to patients sooner
Applying integrated and efficient translational science to develop new treatments that help combat and cure diseases.
Our Pipeline
Our extensive experience and unique drug development engine enable us to identify and incubate high-potential novel drug candidates and rapidly deliver partner-ready clinical assets. Our lead technology platform is our proprietary Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP), which can be applied across multiple therapy areas and indications. PDSP is a multifunctional secreted protein that has anti-angiogenic, anti-tumorigenic, and neurotrophic functions. This platform opens up exciting possibilities for wound healing and tissue regeneration due to its ability to enhance cell proliferation.
Worldwide license for developing PDSP
In 2015, BRIM was granted an exclusive, worldwide license for developing PDSP in all therapeutic indications including dry eye syndrome, corneal wound healing, diabetic ulcer wound healing, osteoarthritis, androgenic alopecia, and muscle/tendon regeneration.
About Us
Our Corporate Milestones
World leading expertise in translational science has enabled BRIM to rapidly advance several discoveries into the clinic and successfully spin-out Ascendo Biotechnology, Inc in 2019.
Our stem cell regenerative Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP) technology platform underpins several products in our pipeline and has the potential to be effective in multiple therapy areas and indications.
Our Expertise
BRIM’s extensive experience and successful track record of translating discovery research to the clinic enables us to identify and incubate high-potential novel drug candidates through our unique drug development engine to deliver partner-ready clinical assets.
Our Core Competencies
- Identifying high-potential technology
- Incubating promising discoveries
- Integrating diverse expertise
- Innovating disease-modifying treatments
- Inspiring entrepreneurial talent
- Implementing efficient translational science
Mission
To advance promising discoveries into disease-modifying treatments that transform patients’ lives.
Vision
To inspire and nurture the next generation of biotech entrepreneurs to bring sustainable and affordable healthcare innovation to the world.
Values
- Mentorship
- Integrity
- Transformation